Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Mansour, H. Khachaturian, M. Lewis, H. Akil, S. Watson (1988)
Anatomy of CNS opioid receptorsTrends in Neurosciences, 11
J. Corchero, J. Oliva, C. Garcı́a-Lecumberri, Sonsoles Martı́n, E. Ambrosio, J. Manzanares (2004)
Repeated administration with δ9- tetrahydrocannabinol regulates µ-opioid receptor density in the rat brainJournal of Psychopharmacology, 18
G. Pugh, D. Mason, Vera Combs, S. Welch (1997)
Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.The Journal of pharmacology and experimental therapeutics, 281 2
D. Cichewicz, Erin Mccarthy (2003)
Antinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral AdministrationJournal of Pharmacology and Experimental Therapeutics, 304
F. D'amour, Donn Smith (1941)
A METHOD FOR DETERMINING LOSS OF PAIN SENSATIONJournal of Pharmacology and Experimental Therapeutics, 72
NM Ellison (1993)
Cancer pain
G. Pugh, S. Welch, Pam Bass (1994)
Modulation of free intracellular calcium and cAMP by morphine and cannabinoids, alone and in combination in mouse brain and spinal cord synaptosomesPharmacology Biochemistry and Behavior, 49
P. Mailleux, J. Vanderhaeghen (1992)
Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistryNeuroscience, 48
T. Rubino, G. Patrini, P. Massi, D. Fuzio, D. Vigano', G. Giagnoni, D. Parolaro (1998)
Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.The Journal of pharmacology and experimental therapeutics, 285 2
Jose Rodriguez, K. Mackie, V. Pickel (2001)
Ultrastructural Localization of the CB1 Cannabinoid Receptor in μ-Opioid Receptor Patches of the Rat Caudate Putamen NucleusThe Journal of Neuroscience, 21
D. Cichewicz, Z. Martin, F. Smith, S. Welch (1999)
Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.The Journal of pharmacology and experimental therapeutics, 289 2
J. Walker, Susan Huang, N. Strangman, Kang Tsou, M. Sañudo‐Peña (1999)
Pain modulation by release of the endogenous cannabinoid anandamide.Proceedings of the National Academy of Sciences of the United States of America, 96 21
A. Hohmann, E. Briley, M. Herkenham (1999)
Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cordBrain Research, 822
D. Cichewicz, S. Welch (2003)
Modulation of Oral Morphine Antinociceptive Tolerance and Naloxone-Precipitated Withdrawal Signs by Oral Δ9-TetrahydrocannabinolJournal of Pharmacology and Experimental Therapeutics, 305
S. Welch, D. Stevens (1992)
Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.The Journal of pharmacology and experimental therapeutics, 262 1
P. Smith, S. Welch, B. Martin (1994)
Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.The Journal of pharmacology and experimental therapeutics, 268 3
C. Salio, J. Fischer, M. Franzoni, K. Mackie, T. Kaneko, M. Conrath (2001)
CB1-cannabinoid and μ-opioid receptor co-localization on postsynaptic target in the rat dorsal hornNeuroreport, 12
T. Rubino, L. Tizzoni, D. Vigano', P. Massi, D. Parolaro (1997)
Modulation of rat brain cannabinoid receptors after chronic morphine treatmentNeuroReport, 8
D. Cichewicz (2004)
Synergistic interactions between cannabinoid and opioid analgesics.Life sciences, 74 11
F. Campbell, Martin TramŁr, D. Carroll, John Reynolds, A. Moore, H. McQuay, R. Moore (2001)
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic reviewBMJ : British Medical Journal, 323
S. Thorat, H. Bhargava (1994)
Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice.European journal of pharmacology, 260 1
P. Massi, A. Vaccani, Stefano Romorini, D. Parolaro (2001)
Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effectsJournal of Neuroimmunology, 117
S. Welch (1997)
Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.Drug and alcohol dependence, 45 1-2
M. Herkenham, Abigail Lynn, M.Ross Johnson, L. Melvin, B. Costa, K. Rice (1991)
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study, 11
J. Mao, Donald Price, Juan Lu, Leslie Keniston, David Mayer (2000)
Two distinctive antinociceptive systems in rats with pathological painNeuroscience Letters, 280
G. Paxinos, Charles Watson (1983)
The Rat Brain in Stereotaxic Coordinates
J. Manzanares, J. Corchero, J. Romero, J. Fernández-Ruiz, J. Ramos, J. Fuentes (1999)
Pharmacological and biochemical interactions between opioids and cannabinoids.Trends in pharmacological sciences, 20 7
SA Varvel, DL Cichewicz, AH Lichtman (2004)
Recent advances in pharmacology and physiology of cannabinoids
L. Sim, D. Selley, R. Xiao, S. Childers (1996)
Differences in G-protein activation by μ-and δ-opioid, and cannabinoid, receptors in rat striatumEuropean Journal of Pharmacology, 307
M. Ware, Crystal Doyle, R. Woods, M. Lynch, A. Clark (2003)
Cannabis use for chronic non-cancer pain: results of a prospective surveyPain, 102
I. Meng, B. Manning, W. Martin, H. Fields (1998)
An analgesia circuit activated by cannabinoidsNature, 395
D. Vigano', M. Cascio, T. Rubino, F. Fezza, A. Vaccani, V. Marzo, D. Parolaro (2003)
Chronic Morphine Modulates the Contents of the Endocannabinoid, 2-Arachidonoyl Glycerol, in Rat BrainNeuropsychopharmacology, 28
J. Corchero, J. Romero, F. Berrendero, J. Fernández-Ruiz, J. Ramos, Jose Fuentes, J. Manzanares (1999)
Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen.Brain research. Molecular brain research, 67 1
A. Lichtman, Stacie Cook, Billy Martin (1996)
Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.The Journal of pharmacology and experimental therapeutics, 276 2
J. Romero, J. Fernández-Ruiz, G. Vela, M. Ruiz‐Gayo, J. Fuentes, J. Ramos (1998)
Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice.Drug and alcohol dependence, 50 3
S. Welch, C. Thomas, G. Patrick (1995)
Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.The Journal of pharmacology and experimental therapeutics, 272 1
C. Ashton (1999)
Adverse effects of cannabis and cannabinoids.British journal of anaesthesia, 83 4
M. Shapira, M. Gafni, Y. Sarne (1998)
Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cellsBrain Research, 806
S. González, J. Fernández-Ruiz, Valentina Sparpaglione, D. Parolaro, J. Ramos (2002)
Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels.Drug and alcohol dependence, 66 1
I. Reche, J. Fuentes, M. Ruiz‐Gayo (1996)
Potentiation of Δ9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of μ- and κ-opioid receptorsEuropean Journal of Pharmacology, 318
M. Bradford (1976)
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.Analytical biochemistry, 72
S. González, P. Schmid, J. Fernández-Ruiz, R. Krebsbach, H. Schmid, J. Ramos (2003)
Region‐dependent changes in endocannabinoid transmission in the brain of morphine‐dependent ratsAddiction Biology, 8
J. Walker, A. Hohmann, W. Martin, N. Strangman, S. Huang, K. Tsou (1999)
The neurobiology of cannabinoid analgesia.Life sciences, 65 6-7
Martin TramŁr, D. Carroll, F. Campbell, John Reynolds, A. Moore, H. McQuay, R. Moore (2001)
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic reviewBMJ : British Medical Journal, 323
J. Sawynok (2003)
Topical and Peripherally Acting AnalgesicsPharmacological Reviews, 55
David Rowen, J. Embrey, C. Moore, S. Welch (1998)
Antisense Oligodeoxynucleotides to the Kappa1 Receptor Enhance Δ9-THC–Induced Antinociceptive TolerancePharmacology Biochemistry and Behavior, 59
M. Shapira, M. Gafni, Y. Sarne (2003)
Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulationBrain Research, 960
I Reche, JA Fuentes, M Ruiz-Gayo (1996)
Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptorsEur J Pharmacol, 318
F. Smith, D. Cichewicz, Z. Martin, S. Welch (1998)
The Enhancement of Morphine Antinociception in Mice by Δ9-TetrahydrocannabinolPharmacology Biochemistry and Behavior, 60
The aim of this work was to study the mechanism of cross-modulation between cannabinoid and opioid systems for analgesia during acute and chronic exposure. Acute coadministration of ineffectual subanalgesic doses of the synthetic cannabinoid CP-55,940 (0.2 mg/kg i.p.) and morphine (2.5 mg/kg i.p.) resulted in significant antinociception. In chronic studies, a low dose of CP-55,940 (0.2 mg/kg, i.p.) that per se did not induce analgesia in naive animals produced a significant degree of antinociception in rats made tolerant to morphine, whereas in rats made tolerant to CP-55,940, morphine challenge did not produce any analgesic response. To identify the mechanism of these asymmetric interactions during chronic treatment, we investigated the functional activity of cannabinoid and μ opioid receptors and their effects on the cyclic AMP (cAMP) cascade. Autoradiographic-binding studies indicated a slight but significant reduction in cannabinoid receptor levels in the hippocampus and cerebellum of morphine-tolerant rats, whereas CP-55,940-stimulated ( 35 S)GTPγS binding showed a significant decrease in receptor/G protein coupling in the limbic area. In CP-55,940 exposed rats, μ opioid receptor binding was significantly raised in the lateral thalamus and periaqueductal gray (PAG), with an increase in DAMGO-stimulated ( 35 S)GTPγS binding in the nucleus accumbens. Finally, we tested the cAMP system's responsiveness to the cannabinoid and opioid in the striatum and dorsal mesencephalon. In vivo chronic morphine did not affect CP-55,940's ability to inhibit forskolin-stimulated cAMP production in vitro and actually induced sensitization in striatal membranes. In contrast, in vivo chronic CP-55,940 desensitized DAMGO's efficacy in inhibiting forskolin-stimulated cAMP production in vitro. The alterations to the cAMP system seem to mirror the behavioral responses, indicating that the two systems may interact at the postreceptor level. This might open up new therapeutic opportunities for relief of chronic pain through cannabinoid–opioid coadministration.
Psychopharmacology – Springer Journals
Published: Nov 1, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.